

Attorney Docket No.: RTS-0258  
Inventors: Bennett and Freier  
Serial No.: 09/910,185  
Filing Date: July 18, 2001  
Page 3

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of the Claims:**

Claim 1 (currently amended): A chemically modified compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human glioma-associated oncogene-3 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding human glioma-associated oncogene-3 and inhibits the expression of human glioma-associated oncogene-3.

Claim 2 (original): The compound of claim 1 which is a antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney Docket No.: RTS-0258  
Inventors: Bennett and Freier  
Serial No.: 09/910,185  
Filing Date: July 18, 2001  
Page 4

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 which is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously presented): A method of inhibiting the expression of glioma-associated oncogene-3 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of glioma-associated oncogene-3 is inhibited.

Attorney Docket No.: RTS-0258  
Inventors: Bennett and Freier  
Serial No.: 09/910,185  
Filing Date: July 18, 2001  
Page 5

Claims 16-20 (canceled).

Claim 21 (new): A method of screening for a modulator of glioma-associated oncogene-3, the method comprising the steps of:

- a. contacting a preferred target segment of a nucleic acid molecule encoding glioma-associated oncogene-3 with one or more candidate modulators of glioma-associated oncogene-3, and
- b. identifying one or more modulators of glioma-associated oncogene-3 expression which modulate the expression of glioma-associated oncogene-3.

Claim 22 (new): The method of claim 21 wherein the modulator of glioma-associated oncogene-3 expression comprises an oligonucleotide, an antisense oligonucleotide, a DNA oligonucleotide, an RNA oligonucleotide, an RNA oligonucleotide having at least a portion of said RNA oligonucleotide capable of hybridizing with RNA to form an oligonucleotide-RNA duplex, or a chimeric oligonucleotide.